A detailed history of Exodus Point Capital Management, LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 37,354 shares of NBIX stock, worth $5.2 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
37,354
Previous 31,788 17.51%
Holding current value
$5.2 Million
Previous $3.58 Million 44.07%
% of portfolio
0.04%
Previous 0.03%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$130.4 - $143.74 $725,806 - $800,056
5,566 Added 17.51%
37,354 $5.15 Million
Q3 2023

Nov 09, 2023

SELL
$94.02 - $117.1 $7.98 Million - $9.94 Million
-84,917 Reduced 72.76%
31,788 $3.58 Million
Q2 2023

Aug 10, 2023

SELL
$89.53 - $104.87 $5.13 Million - $6.01 Million
-57,295 Reduced 32.93%
116,705 $11 Million
Q1 2023

May 11, 2023

BUY
$94.11 - $123.02 $9.5 Million - $12.4 Million
100,994 Added 138.34%
174,000 $17.6 Million
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $2.35 Million - $2.8 Million
22,025 Added 43.2%
73,006 $8.72 Million
Q3 2022

Nov 10, 2022

SELL
$92.03 - $107.81 $1.12 Million - $1.32 Million
-12,207 Reduced 19.32%
50,981 $5.42 Million
Q2 2022

Aug 19, 2022

BUY
$75.79 - $100.07 $1.22 Million - $1.61 Million
16,066 Added 34.09%
63,188 $6.16 Million
Q1 2022

May 13, 2022

SELL
$72.45 - $94.81 $1.42 Million - $1.86 Million
-19,618 Reduced 29.39%
47,122 $4.42 Million
Q4 2021

Feb 11, 2022

BUY
$79.65 - $106.22 $3.26 Million - $4.34 Million
40,867 Added 157.95%
66,740 $5.68 Million
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $2.54 Million - $2.92 Million
-29,521 Reduced 53.29%
25,873 $2.48 Million
Q2 2021

Aug 16, 2021

BUY
$89.43 - $102.27 $4.95 Million - $5.67 Million
55,394 New
55,394 $5.39 Million
Q1 2021

May 17, 2021

SELL
$87.57 - $119.4 $611,501 - $833,770
-6,983 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$86.91 - $108.33 $1.03 Million - $1.28 Million
-11,840 Reduced 62.9%
6,983 $669,000
Q3 2020

Nov 16, 2020

SELL
$96.16 - $135.15 $707,064 - $993,757
-7,353 Reduced 28.09%
18,823 $1.81 Million
Q2 2020

Aug 14, 2020

SELL
$85.09 - $130.36 $247,867 - $379,738
-2,913 Reduced 10.01%
26,176 $3.19 Million
Q1 2020

May 15, 2020

BUY
$75.11 - $113.76 $2.18 Million - $3.31 Million
29,089 New
29,089 $2.52 Million
Q4 2019

Feb 14, 2020

SELL
$86.8 - $118.57 $3.88 Million - $5.31 Million
-44,746 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $578,944 - $701,060
6,907 Added 18.25%
44,746 $4.03 Million
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $1.03 Million - $1.3 Million
-14,219 Reduced 27.31%
37,839 $3.2 Million
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $2.58 Million - $3.41 Million
37,225 Added 250.96%
52,058 $4.59 Million
Q4 2018

Feb 14, 2019

BUY
$68.32 - $124.36 $1.01 Million - $1.84 Million
14,833 New
14,833 $1.06 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.3B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.